Non-alcoholic fatty liver disease (NAFLD), a condition characterized by excessive fat accumulation in the liver, is emerging as a global health concern. Despite its increasing prevalence, NAFLD often remains underdiagnosed due to its asymptomatic nature during early stages. This article aims to provide comprehensive insights into NAFLD to enhance detection, diagnosis, and treatment.
NAFLD is the most common chronic liver disease worldwide, affecting approximately 25% of the global population. The prevalence is higher in individuals with obesity, type 2 diabetes, and metabolic syndrome. Other factors such as sedentary lifestyle and poor dietary habits also contribute to its onset.
NAFLD often presents without symptoms until the disease has significantly progressed. When symptoms do occur, they may include fatigue, right upper quadrant discomfort, and hepatomegaly. Diagnosis typically involves a combination of clinical evaluation, imaging studies, and liver biopsy, if necessary.
Currently, there are no approved pharmacological therapies for NAFLD. The mainstay of treatment is lifestyle modification, including dietary changes and regular physical activity. In severe cases or when cirrhosis is present, liver transplantation may be considered.
Healthcare professionals play a pivotal role in the early detection and management of NAFLD. Routine screening of high-risk individuals, patient education on lifestyle modifications, and regular monitoring for disease progression are crucial.
NAFLD is a significant health issue with a high global prevalence. Early detection and intervention can prevent disease progression and associated complications. As healthcare professionals, we must remain vigilant in identifying and managing this often silent disease to improve patient outcomes.
1.
Combo Therapy Boosts Early CML Response but Not Long Term
2.
PNH With Extravascular Hemolysis Approves Factor D Inhibitor.
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
5.
Classifying childhood brain cancers by immune response may improve diagnostics and treatments
1.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
2.
Decoding Hamartomas: Understanding Their Causes and Symptoms
3.
Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Efficient Management of First line ALK-rearranged NSCLC
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation